← Therapy pipeline
Investigational · Obesity development

Petrelintide + enicepatide

Roche / Zealand Pharma

Amylin plus GIP/GLP-1 combination tested against components.

amylinGLP-1GIP
Obesity stagePhase 2Updated as of November 2026
SponsorRoche / Zealand Pharma
Targetsamylin + GLP-1 + GIP
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Results availability

No numerical results shown

No numerical study results are currently summarized for this profile. The development stage and linked studies are listed below.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIPTargeted
GCGglucagon—
AMYamylinTargeted
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

Co-administered injectionInjection · Once weekly
Phase 2ZYNERGY initiation announced November 18 by Zealand
Milestone → next

Latest: Zealand announced initiation of ZYNERGY on November 18, 2026. The 40-week trial compares three regimens of once-weekly petrelintide plus enicepatide with each component alone and placebo.

Next: Week-40 body-weight change, safety and tolerability.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Related conditions and outcomes

Phase 2 studies1 record

Phase 2

ZYNERGY

Combination development
Study: Not yet recruiting per registryResults: No registry results posted yetStatus reviewed November 2026

Adults with obesity or overweight with a weight-related complication. Zealand announced initiation November 18. The latest registry posting, November 3, lists an estimated November 30 start and estimated enrollment of 486. The sponsor did not report a first dose date.